Video

VintaBio Capacity Update July 2024: Cell & Gene Therapy

Source: VintaBio

In this presentation from the July 2024 OPCU event, Jennifer Kingsley, Chief Commercial Officer at VintaBio, discusses how VintaBio has created open capacity for AAV clinical manufacturing through its streamlined VintaProcess platform which is an intensified adherent AAV process with very low impurities yet exceptionally higher yields than suspension processes resulting in greater than 95% full capsids in a small footprint.

access the Video!

Get unlimited access to:
Trend and Thought Leadership Articles
Case Studies & White Papers
Extensive Product Database
Members-Only Premium Content
Welcome Back! Please Log In to Continue. X

Enter your credentials below to log in. Not yet a member of Outsourced Pharma? Subscribe today.

Subscribe to Outsourced Pharma X

Please enter your email address and create a password to access the full content, Or log in to your account to continue.

or

Subscribe to Outsourced Pharma

Please tell us more about you so that we can customize our newsletters to your specific interests:

What topics interest you? (Check all that apply.)

VintaBio